BIO TECHNOLOGY GENERAL ( BTG )
128
0 ne of the first biologic companies in Israel , Bio Technology General ( BTG ) has become one of the most highly respected businesses in the industry . Housing significant expertise , the company supports startups in the country and is responsible for the development , production and marketing of growth hormone Somatropin , EUFLEXXA for osteoarthritis sufferers and Biolon for ophthalmic surgeries . The company also responsible for the production of new API for fertility treatment - Recovelle
Driving high quality standards across its operations , BTG has been recognised by the Israeli Ministry of Health for its commitment and unwavering focus on delivering high quality pharmaceuticals , which are commercialised in over 40 countries . The company is also set to see an investment of up to $ 15mn by its parent company , Ferring Pharmaceuticals , to expand its production capabilities in a mammalian cells operation for the production of fertility medicine . “ We are having a lot of audits from different regulatory authorities each year and are passing all of them with ease . We are very proud of our quality , systems and processes ,” explains Head of Supply Chain , Alon Ben Dror .
Responsible for planning control , logistics , business technology , as well as BTG ’ s pro-
“We need to ensure medicine supplied in high quality , which means controlled shipment and logistics routes , making sure we have the right safety stock for each market ”
— Alon Ben Dror , Head of Supply Chain
JULY 2018